Neuropathic pain (NeP) is a disorder of the nervous system resulting from altered mechanisms operating at the peripheral nervous system, spinal cord and supraspinal levels and is defined by the International Association for the Study of Pain as pain resulting from nervous system pathologies that cause changes in the function, chemistry and structure of neurons . NeP affects 2-8% of the world population and can have a significant impact on the patient's functional abilities and quality of life. NeP can be caused by spinal cord injury, brain and spinal cord tumours and other diseases affecting the nervous system. NeP can be secondary to extremely common conditions such as diabetes, stroke, cancer, herpes zoster virus infection and autoimmune disease. These recommendations were finalised in 2019 and published in April 2020. Following the GRADE system, the recommendations suggest first-line treatment options including serotonin-noradrenaline reuptake inhibitors (duloxetine and venlafaxine), gabapentin, tricyclic antidepressants, and the specialised use of topical lidocaine and transcutaneous electrical nerve stimulation for peripheral neuropathic pain. Pregabalin, tramadol and combination therapy (combining antidepressants with gabapentinoids) are recommended as second-line treatments. Highly concentrated capsaicin patches and botulinum toxin A are recommended as second-line treatments, especially for focal peripheral neuropathic pain. Third-line treatment options include high-frequency repetitive transcranial magnetic stimulation (rTMS) of the primary motor cortex (motor cotex-1/M1), spinal cord stimulation (for failed back surgery syndrome and painful diabetic polyneuropathy) and strong opioids as a last resort in the absence of alternatives. In addition, psychotherapy, including cognitive behavioural therapy and mindfulness, is recommended as second-line treatment in combination with other therapies. Pregabalin is also used in the treatment of epilepsy by blocking and modulating the α2 δ subunit of voltage-dependent calcium channels. There are studies showing that antiepileptics cause folate and vitamin B12 deficiency in epilepsy patients. In our study, we aimed to retrospectively analyse vitamin B12 and folic acid levels before and after treatment in patients using antiepileptics (anticonvulsants) for neuropathic pain.
After the acceptance of the study (after obtaining ethics committee approval), patients who have been followed up for at least 6 months in the physical medicine and rehabilitation outpatient clinic with a diagnosis of neuropathic pain and who use pregabalin will be evaluated retrospectively (1-year records). Blood vitamin B12 and folate (folic acid) levels of the patients before and after pregabalin use will be determined. Patients will be evaluated whether there is a change in vitamin B12 and folic acid levels due to drug use.
Study Type
OBSERVATIONAL
Enrollment
96
Gaziosmanpasa Research and Education Hospital
Istanbul, Gaziosmanpasa, Turkey (Türkiye)
Vitamin B12 level analysed before treatment (pre-treatment) (retrospective)
Vitamin B12 level (pg/mL) among the laboratory parameters analysed before antiepileptic treatment (pre-treatment) for neuropathic pain will be screened retrospectively. Patients who applied to the physical medicine and rehabilitation clinic with a diagnosis of neuropathic pain in the last 6 months (June-December 2024) before the ethics committee application date, who were followed up with this diagnosis and started antiepileptic treatment will be screened within 1 month.
Time frame: Within 1 month
Vitamin B12 level analysed after treatment (post-treatment) (retrospective)
Vitamin B12 level (pg/mL) among the laboratory parameters analysed after antiepileptic treatment (post-treatment) for neuropathic pain will be screened retrospectively. Patients who applied to the physical medicine and rehabilitation clinic with a diagnosis of neuropathic pain in the last 6 months (June-December 2024) before the ethics committee application date, who were followed up with this diagnosis and started antiepileptic treatment will be screened within 1 month.
Time frame: Within 1 month
Folic acid level analysed before treatment (pre-treatment) (retrospective)
Folic acid level (ng/mL), one of the laboratory parameters analysed before antiepileptic treatment for neuropathic pain (pre-treatment), will be screened retrospectively. Patients who applied to the physical medicine and rehabilitation clinic with a diagnosis of neuropathic pain in the last 6 months (June-December 2024) before the ethics committee application date, who were followed up with this diagnosis and started antiepileptic treatment will be screened within 1 month.
Time frame: Within 1 month
Folic acid level analysed after treatment (post-treatment) (retrospective)
Folic acid level (ng/mL), one of the laboratory parameters analysed after antiepileptic treatment for neuropathic pain (post-treatment), will be screened retrospectively. Patients who applied to the physical medicine and rehabilitation clinic with a diagnosis of neuropathic pain in the last 6 months (June-December 2024) before the ethics committee application date, who were followed up with this diagnosis and started antiepileptic treatment will be screened within 1 month.
Time frame: Within 1 month
25-OH Vitamin D level analysed before treatment (pre-treatment) (retrospective)
D vitamini (25-OH Vitamin D) (ng/mL) among the laboratory parameters analysed before antiepileptic treatment (pre-treatment) for neuropathic pain will be screened retrospectively. Patients who applied to the physical medicine and rehabilitation clinic with a diagnosis of neuropathic pain in the last 6 months (June-December 2024) before the ethics committee application date, who were followed up with this diagnosis and started antiepileptic treatment will be screened within 1 month.
Time frame: Within 1 month
25-OH Vitamin D level analysed after treatment (post-treatment) (retrospective)
25-OH Vitamin D (ng/mL) among the laboratory parameters analysed after antiepileptic treatment (post-treatment) for neuropathic pain will be screened retrospectively. Patients who applied to the physical medicine and rehabilitation clinic with a diagnosis of neuropathic pain in the last 6 months (June-December 2024) before the ethics committee application date, who were followed up with this diagnosis and started antiepileptic treatment will be screened within 1 month.
Time frame: Within 1 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.